Figure 1: In vitro pharmacological characterization of CRTH2 inhibitor. Potency of Compound A was examined in human CRTH2 FRET assay a), human CRTH2 competitive radio-ligand binding assay b) human eosinophil shape change assay c) and human basophil chemotaxis assay d). Selectivity of Compound A was conducted in the competitive radio-ligand binding assay for human TP receptor, TXA2R e) and DP1 as described in the materials and methods.